The firm has been developing several new tests that are based on its ADAPT aptamer profiling technology.
The Belgian company recently received €3.6 million to develop the signature into a clinical test within the next three years.
The change comes amid lower than expected revenues for the first half of this year, as well as an anticipated continued lack of reimbursement coverage in the US.
MDxHealth will use Ghent's methylation in situ hybridization technology to develop tests for urological cancers.
The firm is now launching the test in Europe, supported by results from a multicenter prospective study showing high sensitivity in detecting bladder cancer.